Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,400 peer-reviewed publications.

The CPRD bibliography is updated on a monthly basis (last updated 5 February 2020) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download: 

(PDF, 3MB, 197 pages)

 

Export 70 results:
Author Title [ Type(Desc)] Year
Filters: Author is Leufkens, H. G.  [Clear All Filters]
Journal Article
T. P. van Staa, Card, T., Logan, R. F., and Leufkens, H. G., “5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study”, Gut, vol. 54, pp. 1573-8, 2005.
T. P. van Staa, Travis, S., Leufkens, H. G., and Logan, R. F., “5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study”, Gastroenterology, vol. 126, pp. 1733-9, 2004.
E. M. van de Garde, Souverein, P. C., Hak, E., Deneer, V. H., van den Bosch, J. M., and Leufkens, H. G., “Angiotensin-converting enzyme inhibitor use and protection against pneumonia in patients with diabetes”, J Hypertens, vol. 25, pp. 235-9, 2007.
V. Abbing-Karahagopian, Huerta, C., Souverein, P. C., de Abajo, F., Leufkens, H. G., Slattery, J., Alvarez, Y., Miret, M., Gil, M., Oliva, B., Hesse, U., Requena, G., de Vries, F., Rottenkolber, M., Schmiedl, S., Reynolds, R., Schlienger, R. G., de Groot, M. C., Klungel, O. H., van Staa, T. P., van Dijk, L., Egberts, A. C., Gardarsdottir, H., and De Bruin, M. L., “Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications”, Eur J Clin Pharmacol, vol. 70, pp. 849-57, 2014.
C. Klop, Gibson-Smith, D., Elders, P. J., Welsing, P. M., Leufkens, H. G., Harvey, N. C., Bijlsma, J. W., van Staa, T. P., and de Vries, F., “Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000-2010”, Osteoporos Int, vol. 26, pp. 1919-28, 2015.
T. P. van Staa, Bishop, N., Leufkens, H. G., and Cooper, C., “Are inhaled corticosteroids associated with an increased risk of fracture in children?”, Osteoporos Int, vol. 15, pp. 785-91, 2004.
J. H. Driessen, Henry, R. M., van Onzenoort, H. A., Lalmohamed, A., Burden, A. M., Prieto-Alhambra, D., Neef, C., Leufkens, H. G., and de Vries, F., “Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis”, Calcif Tissue Int, vol. 97, pp. 104-12, 2015.
A. Lalmohamed, Bazelier, M. T., van Staa, T. P., Uitdehaag, B. M., Leufkens, H. G., de Boer, A., and de Vries, F., “Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based cohort study”, Eur J Neurol, vol. 19, pp. 1007-14, 2012.
E. Setakis, Leufkens, H. G., and van Staa, T. P., “Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib”, Arthritis Rheum, vol. 59, pp. 1105-11, 2008.
T. P. van Staa, Cooper, C., Leufkens, H. G., and Bishop, N., “Children and the risk of fractures caused by oral corticosteroids”, J Bone Miner Res, vol. 18, pp. 913-8, 2003.
T. P. van Staa, Geusens, P., Bijlsma, J. W., Leufkens, H. G., and Cooper, C., “Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis”, Arthritis Rheum, vol. 54, pp. 3104-12, 2006.
H. A. van den Ham, Klungel, O. H., Singer, D. E., Leufkens, H. G., and van Staa, T. P., “Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: Results From a National Primary Care Database”, J Am Coll Cardiol, vol. 66, pp. 1851-9, 2015.
T. P. van Staa, Leufkens, H. G., Zhang, B., and Smeeth, L., “A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example”, PLoS Med, vol. 6, p. e1000194, 2009.
B. M. Verdel, Souverein, P. C., Egberts, A. C., and Leufkens, H. G., “Difference in risks of allergic reaction to sulfonamide drugs based on chemical structure”, Ann Pharmacother, vol. 40, pp. 1040-6, 2006.
T. P. van Staa, Leufkens, H. G., and Cooper, C., “Does a fracture at one site predict later fractures at other sites? A British cohort study”, Osteoporos Int, vol. 13, pp. 624-9, 2002.
T. P. van Staa, Rietbrock, S., Setakis, E., and Leufkens, H. G., “Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?”, J Intern Med, vol. 264, pp. 481-92, 2008.
C. Cooper, Dennison, E. M., Leufkens, H. G., Bishop, N., and van Staa, T. P., “Epidemiology of childhood fractures in Britain: a study using the general practice research database”, J Bone Miner Res, vol. 19, pp. 1976-81, 2004.
T. P. van Staa, Dennison, E. M., Leufkens, H. G., and Cooper, C., “Epidemiology of fractures in England and Wales”, Bone, vol. 29, pp. 517-22, 2001.
T. P. van Staa, Smeeth, L., Persson, I., Parkinson, J., and Leufkens, H. G., “Evaluating drug toxicity signals: is a hierarchical classification of evidence useful or a hindrance?”, Pharmacoepidemiol Drug Saf, vol. 17, pp. 475-84, 2008.
S. Pouwels, de Boer, A., Javaid, M. K., Hilton-Jones, D., Verschuuren, J., Cooper, C., Leufkens, H. G., and de Vries, F., “Fracture rate in patients with myasthenia gravis: the general practice research database”, Osteoporos Int, vol. 24, pp. 467-76, 2013.
F. de Vries, Bracke, M., Leufkens, H. G., Lammers, J. W., Cooper, C., and van Staa, T. P., “Fracture risk with intermittent high-dose oral glucocorticoid therapy”, Arthritis Rheum, vol. 56, pp. 208-14, 2007.
A. M. Gallagher, Williams, T., Leufkens, H. G., and de Vries, F., “The Impact of the Choice of Data Source in Record Linkage Studies Estimating Mortality in Venous Thromboembolism”, PLoS One, vol. 11, p. e0148349, 2016.
T. P. van Staa, Selby, P., Leufkens, H. G., Lyles, K., Sprafka, J. M., and Cooper, C., “Incidence and natural history of Paget's disease of bone in England and Wales”, J Bone Miner Res, vol. 17, pp. 465-71, 2002.
T. P. van Staa, Geusens, P., Zhang, B., Leufkens, H. G., Boonen, A., and Cooper, C., “Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids”, Rheumatology (Oxford), vol. 46, pp. 460-6, 2007.
T. P. van Staa, Cooper, C., Barlow, D., and Leufkens, H. G., “Individualizing the risks and benefits of postmenopausal hormone therapy”, Menopause, vol. 15, pp. 374-81, 2008.
P. J. Peeters, Bazelier, M. T., Leufkens, H. G., Auvinen, A., van Staa, T. P., de Vries, F., and De Bruin, M. L., “Insulin glargine use and breast cancer risk: Associations with cumulative exposure”, Acta Oncol, vol. 55, pp. 851-8, 2016.
I. Wilting, de Vries, F., Thio, B. M., Cooper, C., Heerdink, E. R., Leufkens, H. G., Nolen, W. A., Egberts, A. C., and van Staa, T. P., “Lithium use and the risk of fractures”, Bone, vol. 40, pp. 1252-8, 2007.
J. H. Driessen, van den Bergh, J. P., van Onzenoort, H. A., Henry, R. M., Leufkens, H. G., and de Vries, F., “Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study”, Diabetes Obes Metab, vol. 19, pp. 421-428, 2017.
C. Klop, Welsing, P. M., Cooper, C., Harvey, N. C., Elders, P. J., Bijlsma, J. W., Leufkens, H. G., and de Vries, F., “Mortality in British hip fracture patients, 2000-2010: a population-based retrospective cohort study”, Bone, vol. 66, pp. 171-7, 2014.
T. P. van Staa, Boulton, F., Cooper, C., Hagenbeek, A., Inskip, H., and Leufkens, H. G., “Neutropenia and agranulocytosis in England and Wales: incidence and risk factors”, Am J Hematol, vol. 72, pp. 248-54, 2003.
T. P. van Staa, Leufkens, H. G., Abenhaim, L., Zhang, B., and Cooper, C., “Oral corticosteroids and fracture risk: relationship to daily and cumulative doses”, Rheumatology (Oxford), vol. 39, pp. 1383-9, 2000.
H. A. van den Ham, Klungel, O. H., Leufkens, H. G., and van Staa, T. P., “The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation”, J Thromb Haemost, vol. 11, pp. 107-15, 2013.
A. Lalmohamed, Macgregor, A. J., de Vries, F., Leufkens, H. G., and van Staa, T. P., “Patterns of risk of cancer in patients with metal-on-metal hip replacements versus other bearing surface types: a record linkage study between a prospective joint registry and general practice electronic health records in England”, PLoS One, vol. 8, p. e65891, 2013.
C. Klop, de Vries, F., Bijlsma, J. W., Leufkens, H. G., and Welsing, P. M., “Predicting the 10-year risk of hip and major osteoporotic fracture in rheumatoid arthritis and in the general population: an independent validation and update of UK FRAX without bone mineral density”, Ann Rheum Dis, vol. 75, pp. 2095-2100, 2016.
M. J. Willemen, Mantel-Teeuwisse, A. K., Straus, S. M., Leufkens, H. G., and Egberts, A. C., “Psychiatric and cardiovascular comorbidities in patients with diabetes mellitus starting antiobesity drugs”, Obesity (Silver Spring), vol. 16, pp. 2331-5, 2008.
T. P. van Staa, Abenhaim, L., Cooper, C., Zhang, B., and Leufkens, H. G., “Public health impact of adverse bone effects of oral corticosteroids”, Br J Clin Pharmacol, vol. 51, pp. 601-7, 2001.
J. P. Yska, van Roon, E. N., de Boer, A., Leufkens, H. G., Wilffert, B., de Heide, L. J., de Vries, F., and Lalmohamed, A., “Remission of Type 2 Diabetes Mellitus in Patients After Different Types of Bariatric Surgery: A Population-Based Cohort Study in the United Kingdom”, JAMA Surg, vol. 150, pp. 1126-33, 2015.
K. B. Handoko, Souverein, P. C., van Staa, T. P., Meyboom, R. H., Leufkens, H. G., Egberts, T. C., and van den Bemt, P. M., “Risk of aplastic anemia in patients using antiepileptic drugs”, Epilepsia, vol. 47, pp. 1232-6, 2006.
M. T. Bazelier, Mueller-Schotte, S., Leufkens, H. G., Uitdehaag, B. M., Van Staa, T., and de Vries, F., “Risk of cataract and glaucoma in patients with multiple sclerosis”, Mult Scler, vol. 18, pp. 628-38, 2012.
P. J. Peeters, Bazelier, M. T., Leufkens, H. G., de Vries, F., and De Bruin, M. L., “The risk of colorectal cancer in patients with type 2 diabetes: associations with treatment stage and obesity”, Diabetes Care, vol. 38, pp. 495-502, 2015.
A. M. Gallagher, Smeeth, L., Seabroke, S., Leufkens, H. G., and van Staa, T. P., “Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data”, PLoS One, vol. 6, p. e28157, 2011.
S. Pouwels, de Boer, A., Leufkens, H. G., Weber, W. E., Cooper, C., and de Vries, F., “Risk of fracture in patients with Charcot-Marie-Tooth disease”, Muscle Nerve, vol. 50, pp. 919-24, 2014.
S. Pouwels, de Boer, A., Leufkens, H. G., Weber, W. E., Cooper, C., van Staa, T. P., and de Vries, F., “Risk of fracture in patients with Guillain-Barre syndrome”, Osteoporos Int, vol. 25, pp. 1845-51, 2014.
M. T. Bazelier, Van Staa, T., Uitdehaag, B. M., Cooper, C., Leufkens, H. G., Vestergaard, P., Bentzen, J., and de Vries, F., “The risk of fracture in patients with multiple sclerosis: the UK general practice research database”, J Bone Miner Res, vol. 26, pp. 2271-9, 2011.
S. Pouwels, de Boer, A., Leufkens, H. G., Weber, W. E., Cooper, C., van Onzenoort, H. A., and de Vries, F., “Risk of fracture in patients with muscular dystrophies”, Osteoporos Int, vol. 25, pp. 509-18, 2014.
M. T. Bazelier, de Vries, F., Vestergaard, P., Herings, R. M., Gallagher, A. M., Leufkens, H. G., and van Staa, T. P., “Risk of fracture with thiazolidinediones: an individual patient data meta-analysis”, Front Endocrinol (Lausanne), vol. 4, p. 11, 2013.
J. van Dalem, Brouwers, M. C., Stehouwer, C. D., Krings, A., Leufkens, H. G., Driessen, J. H., de Vries, F., and Burden, A. M., “Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study”, Bmj, vol. 354, p. i3625, 2016.
B. Spaetgens, de Vries, F., Driessen, J. H. M., Leufkens, H. G., Souverein, P. C., Boonen, A., van der Meer, J. W. M., and Joosten, L. A. B., “Risk of infections in patients with gout: a population-based cohort study”, Sci Rep, vol. 7, p. 1429, 2017.
D. Gibson-Smith, Klop, C., Elders, P. J., Welsing, P. M., van Schoor, N., Leufkens, H. G., Harvey, N. C., van Staa, T. P., and de Vries, F., “The risk of major and any (non-hip) fragility fracture after hip fracture in the United Kingdom: 2000-2010”, Osteoporos Int, vol. 25, pp. 2555-63, 2014.
P. J. Peeters, Bazelier, M. T., Uitdehaag, B. M., Leufkens, H. G., De Bruin, M. L., and de Vries, F., “The risk of venous thromboembolism in patients with multiple sclerosis: the Clinical Practice Research Datalink”, J Thromb Haemost, vol. 12, pp. 444-51, 2014.
[Page last reviewed 5 February 2020]